327 related articles for article (PubMed ID: 15383606)
1. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy.
Bleeker WK; Lammerts van Bueren JJ; van Ojik HH; Gerritsen AF; Pluyter M; Houtkamp M; Halk E; Goldstein J; Schuurman J; van Dijk MA; van de Winkel JG; Parren PW
J Immunol; 2004 Oct; 173(7):4699-707. PubMed ID: 15383606
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
3. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
[TBL] [Abstract][Full Text] [Related]
4. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A.
Ciardiello F; Damiano V; Bianco R; Bianco C; Fontanini G; De Laurentiis M; De Placido S; Mendelsohn J; Bianco AR; Tortora G
J Natl Cancer Inst; 1996 Dec; 88(23):1770-6. PubMed ID: 8944008
[TBL] [Abstract][Full Text] [Related]
8. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
Schneider-Merck T; Lammerts van Bueren JJ; Berger S; Rossen K; van Berkel PH; Derer S; Beyer T; Lohse S; Bleeker WK; Peipp M; Parren PW; van de Winkel JG; Valerius T; Dechant M
J Immunol; 2010 Jan; 184(1):512-20. PubMed ID: 19949082
[TBL] [Abstract][Full Text] [Related]
9. EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
Caraglia M; Marra M; Meo G; Addeo SR; Tagliaferri P; Budillon A
Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):209-22. PubMed ID: 18221038
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition.
Overdijk MB; Verploegen S; van den Brakel JH; Lammerts van Bueren JJ; Vink T; van de Winkel JG; Parren PW; Bleeker WK
J Immunol; 2011 Sep; 187(6):3383-90. PubMed ID: 21832160
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
Modjtahedi H; Eccles S; Box G; Styles J; Dean C
Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations.
Perez-Torres M; Guix M; Gonzalez A; Arteaga CL
J Biol Chem; 2006 Dec; 281(52):40183-92. PubMed ID: 17082181
[TBL] [Abstract][Full Text] [Related]
13. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy.
Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG
Crit Rev Oncol Hematol; 2001 Apr; 38(1):17-23. PubMed ID: 11255078
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.
Aboud-Pirak E; Hurwitz E; Pirak ME; Bellot F; Schlessinger J; Sela M
J Natl Cancer Inst; 1988 Dec; 80(20):1605-11. PubMed ID: 3193478
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
16. The epidermal growth factor receptor as a target for cancer therapy.
Mendelsohn J
Endocr Relat Cancer; 2001 Mar; 8(1):3-9. PubMed ID: 11350723
[TBL] [Abstract][Full Text] [Related]
17. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Schlaeth M; Berger S; Derer S; Klausz K; Lohse S; Dechant M; Lazar GA; Schneider-Merck T; Peipp M; Valerius T
Cancer Sci; 2010 May; 101(5):1080-8. PubMed ID: 20331636
[TBL] [Abstract][Full Text] [Related]
18. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ
Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906
[TBL] [Abstract][Full Text] [Related]
19. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
[TBL] [Abstract][Full Text] [Related]
20. Novel monoclonal antibody specific for the de2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene.
Johns TG; Stockert E; Ritter G; Jungbluth AA; Huang HJ; Cavenee WK; Smyth FE; Hall CM; Watson N; Nice EC; Gullick WJ; Old LJ; Burgess AW; Scott AM
Int J Cancer; 2002 Mar; 98(3):398-408. PubMed ID: 11920591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]